Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
The series turned a voyeuristic lens to people with unusual habits, but it did raise awareness of various compulsive ...
Hyderabad: India is harnessing science and genomics to build a skilled workforce and ensure timely diagnosis and treatment ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
A rare condition called Eosinophilic Fasciitis caused a 42-year-old engineer severe pain and stiffness. Doctors identified ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...
Millennial Skin on MSN
Weird nail problems doctors say you shouldn’t ignore
Your nails might seem like a purely cosmetic detail, but doctors often see them as tiny windows into your overall health.
Dr Lata BichileMK, a 42-year-old engineer, walked into my OPD along with his wife in August 2023. He had been experiencing ...
Archana Puran Singh diagnosed with rare CRPS chronic pain condition after an injury, revealing how minor injuries can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback